Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of M100907 for sleep maintenance insomnia, with type 2 diabetes sub-study
2006-006677-25Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Sleep initiation and maintenance disorder and type 2 diabetes mellitus (T2DM) comparing Volinanserin 2 mg/day with Placebo (2 arms). Primary endpoint: Change in patient-reported wake after sleep onset (WASO). Started Apr 2007; status: completed.
02
Drugs
volinanserin
03
Conditions
Sleep initiation and maintenance disordertype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006677-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006677-25.